Cumberland Pharmaceuticals (NASDAQ:CPIX) Stock Rating Upgraded by Wall Street Zen

Cumberland Pharmaceuticals (NASDAQ:CPIX) was upgraded by stock analysts at Wall Street Zen to a “hold” rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Cumberland Pharmaceuticals in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Cumberland Pharmaceuticals has a consensus rating of “Sell”.

Cumberland Pharmaceuticals Price Performance

Cumberland Pharmaceuticals stock opened at $4.95 on Friday. The company has a market capitalization of $74.05 million, a price-to-earnings ratio of -20.63 and a beta of -0.53. The company has a current ratio of 1.23, a quick ratio of 1.11 and a debt-to-equity ratio of 0.20. Cumberland Pharmaceuticals has a 12 month low of $1.85 and a 12 month high of $7.25. The stock’s 50 day moving average is $3.01 and its 200-day moving average is $3.21.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last posted its quarterly earnings data on Tuesday, November 4th. The specialty pharmaceutical company reported ($0.06) earnings per share for the quarter. The firm had revenue of $8.29 million for the quarter. Cumberland Pharmaceuticals had a positive return on equity of 5.13% and a negative net margin of 8.06%.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Bridgeway Capital Management LLC boosted its holdings in shares of Cumberland Pharmaceuticals by 2.3% in the 2nd quarter. Bridgeway Capital Management LLC now owns 188,355 shares of the specialty pharmaceutical company’s stock valued at $631,000 after purchasing an additional 4,200 shares in the last quarter. Two Sigma Investments LP lifted its position in shares of Cumberland Pharmaceuticals by 16.5% during the 3rd quarter. Two Sigma Investments LP now owns 37,591 shares of the specialty pharmaceutical company’s stock worth $117,000 after buying an additional 5,326 shares during the last quarter. XTX Topco Ltd bought a new stake in shares of Cumberland Pharmaceuticals during the 2nd quarter worth $34,000. Dimensional Fund Advisors LP boosted its stake in Cumberland Pharmaceuticals by 11.1% in the third quarter. Dimensional Fund Advisors LP now owns 280,869 shares of the specialty pharmaceutical company’s stock valued at $876,000 after buying an additional 27,980 shares in the last quarter. Finally, Heron Bay Capital Management bought a new position in Cumberland Pharmaceuticals in the second quarter valued at about $111,000. 15.51% of the stock is currently owned by institutional investors and hedge funds.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products. Founded in 1993, the company has built a portfolio of branded therapeutics designed to address critical care needs in emergency medicine, critical care units and other hospital settings. Cumberland’s strategy emphasizes in-licensing and acquiring products that have established safety and efficacy profiles but limited market reach, then leveraging its sales network to expand their commercial footprint.

The company’s flagship products include Acetadote (N-acetylcysteine injection), the only FDA-approved antidote for acetaminophen overdose administered intravenously; Vasostrict (vasopressin injection), used to raise blood pressure in adults with vasodilatory shock; Cerebrex (diclofenac sodium injection), an anti-inflammatory agent for managing acute pain and fever; and Dynastat (parecoxib sodium), a COX-2 inhibitor for postoperative pain relief.